{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:48:45Z","timestamp":1781801325049,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01300-1","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:10:35Z","timestamp":1747062635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9487-8345","authenticated-orcid":false,"given":"Craig A.","family":"Portell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opeyemi A.","family":"Jegede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Rosenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-3258","authenticated-orcid":false,"given":"Jeffrey W.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"1300_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA: A Cancer J Clin"},{"key":"1300_CR2","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Ha\u00efoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. JCO. 1997;15:1110\u20137.","journal-title":"JCO"},{"key":"1300_CR3","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"1300_CR4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. JCO. 2017;35:826\u201333.","journal-title":"JCO"},{"key":"1300_CR5","first-page":"2628","volume":"136","author":"PL Zinzani","year":"2020","unstructured":"Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma. Blood. 2020;136:2628\u201337.","journal-title":"Blood"},{"key":"1300_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"1300_CR7","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","volume":"133","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019;133:1964\u201376.","journal-title":"Blood"},{"key":"1300_CR8","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2217\/fon-2022-0112","volume":"18","author":"A Davies","year":"2022","unstructured":"Davies A, Kater AP, Sharman JP, Stilgenbauer S, Vitolo U, Klein C, et al. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncol. 2022;18:2943\u201366.","journal-title":"Future Oncol"},{"key":"1300_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"1300_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1078155214533368","volume":"21","author":"MJ Fallon","year":"2015","unstructured":"Fallon MJ, Heck JN. Fatal Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis induced by allopurinol\u2013rituximab\u2013bendamustine therapy. J Oncol Pharm Pr. 2015;21:388\u201392.","journal-title":"J Oncol Pharm Pr"},{"key":"1300_CR11","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1158\/1078-0432.CCR-20-1345","volume":"26","author":"AM Evens","year":"2020","unstructured":"Evens AM, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, et al. A Three-Arm Randomized Phase II Study of Bendamustine\/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clin Cancer Res. 2020;26:4468\u201377.","journal-title":"Clin Cancer Res"},{"key":"1300_CR12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081\u201393.","journal-title":"Lancet Oncol"},{"key":"1300_CR13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. JCO. 2014;32:3059\u201367.","journal-title":"JCO"},{"key":"1300_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-014-0221-9","volume":"9","author":"N Fedchenko","year":"2014","unstructured":"Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue \u2013 a review. Diagnostic Pathol. 2014;9:221.","journal-title":"Diagnostic Pathol"},{"key":"1300_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3\u201311.","journal-title":"Br J Haematol"},{"key":"1300_CR16","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/his.12076","volume":"62","author":"T Marafioti","year":"2013","unstructured":"Marafioti T, Copie-Bergman C, Calaminici M, Paterson JC, Shende VH, Liu H, et al. Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. Histopathology. 2013;62:860\u201375.","journal-title":"Histopathology"},{"key":"1300_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N. Engl J Med. 2017;377:1331\u201344.","journal-title":"N. Engl J Med"},{"key":"1300_CR18","doi-asserted-by":"publisher","first-page":"e919","DOI":"10.1097\/HS9.0000000000000919","volume":"7","author":"W Townsend","year":"2023","unstructured":"Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, et al. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere. 2023;7:e919.","journal-title":"HemaSphere"},{"key":"1300_CR19","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","volume":"19","author":"J Trotman","year":"2018","unstructured":"Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19:1530\u201342.","journal-title":"Lancet Oncol"},{"key":"1300_CR20","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.18.00359","volume":"36","author":"MS Davids","year":"2018","unstructured":"Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, et al. Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. JCO. 2018;36:3525\u20137.","journal-title":"JCO"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01300-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:10:36Z","timestamp":1747062636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01300-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CAP: Consulting: BeiGene, Janssen\/Pharmacyclics, Kite, Morphosys, AbbVie, Merck, AstraZeneca; Research funding: AbbVie, Roche\/Genentech, Infinity, AstraZeneca, BeiGene, SeaGen\/Pfizer, Merck. OAJ: None. NWJ: Research funding Genentech\/Roche, Merck, Astra Zeneca. GSN: AbbVie, ADC Therapeutics, Bantam Pharmaceutical LLC, Blueprint Medicines, Bristol-Myers Squibb, Celgene Corporation, Curis, Debiopharm, F Hoffmann-La Roche Limited, Fate Therapeutics, Genentech, Incyte, Karyopharm Therapeutics, Kite Pharma, Kymera Therapeutics, MEI Pharma, MorphoSys AG, Ryvu Therapeutics, Seagen, Selvita Inc, TG Therapeutics. CF: None. JBC: Research funding: Genentech, Takeda, BMS\/Celgene, Astra Zeneca, Loxo\/Lilly, Nurix, Novartis; Consultant\/Advisor: Astra Zeneca, ADCT, Loxo\/Lilly, Genentech, HutchMed, Janssen, Beigene. AE: Advisory Board (Research Related): Seattle Genetics\/Pfizer, Incyte, Daiichi Sankyo, Genentech, Novartis; Consultant (Educational Related): Research to Practice, Patient Power, Curio Science, OncLive; Consultant (Data and Safety Monitoring Board): Novartis, Pharmacyclics. LJR: None. JWC: Consultancy and expert testimony for Bayer, and Honoraria from BeiGene. NR: Merck employee. BSK: Consulting- Genentech\/Roche, ADC Therapeutics, Abbvie, AstraZeneca, BeiGene, Celgene\/BMS, Kite, Genmab, Lilly, GSK \/ Research Funding -Genentech\/Roche, Abbvie, AstraZeneca, BeiGen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}